Literature DB >> 2188845

A comparison of the haemodynamic and hormonal effects of low and conventional dose cyclopenthiazide in normal volunteers.

G E McVeigh1, M McMaster, T Linton, E Whitehead, G D Johnston.   

Abstract

In this study we compared low (125 micrograms) and conventional (500 micrograms) doses of cyclopenthiazide on the renin angiotensin system, plasma and extracellular fluid volumes and the pressor responsiveness to angiotensin II since we have previously shown that the two doses have the same antihypertensive effect but different effects on plasma renin activity. Following a two week placebo run-in period, 8 healthy male volunteers received 125 micrograms or 500 micrograms of cyclopenthiazide for 2 treatment periods of 4 weeks as part of a double blind, 2-part crossover study with treatment periods separated by a 4-week placebo washout phase. Measurements were made on two study days at the beginning and end of the active treatment periods. On the first day serum potassium, plasma renin activity and plasma angiotensin II levels were measured after a 1 h period of supine rest. Plasma and extracellular fluid volumes were also measured after appropriate equilibration times. The blood pressure responses to angiotensin II were assessed on day 2. The 500 micrograms dose of cyclopenthiazide had a greater effect than the 125 micrograms dose on plasma renin activity, serum potassium, angiotensin II levels and extracellular fluid volumes. Neither drug had any effect on plasma volume or the responsiveness to infused angiotensin II. Low dose cyclopenthiazide failed to increase angiotensin II levels, contract body fluid volumes or attenuate vascular reactivity in normotensive volunteers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2188845     DOI: 10.1007/bf00315574

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Effect of long-term treatment with chlorothiazide on body fluids, serum electrolytes, and exchangeable sodium in hypertensive patients.

Authors:  P LAUWERS; J CONWAY
Journal:  J Lab Clin Med       Date:  1960-09

2.  Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.

Authors:  J H Laragh
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  Renin-angiotensin-aldosterone system during chronic thiazide therapy of benign hypertension.

Authors:  J J Bourgoignie; F J Catanzaro; H M Perry
Journal:  Circulation       Date:  1968-01       Impact factor: 29.690

5.  Plasma volume in men with essential hypertension.

Authors:  R C Tarazi; E D Frohlich; H P Dustan
Journal:  N Engl J Med       Date:  1968-04-04       Impact factor: 91.245

6.  The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide.

Authors:  G McVeigh; D Galloway; D Johnston
Journal:  BMJ       Date:  1988-07-09

7.  Indomethacin potentiates the vasoconstrictor actions of angiotensin II in normal man.

Authors:  P Negus; R L Tannen; M J Dunn
Journal:  Prostaglandins       Date:  1976-08

8.  Mechanism of decreased vascular reactivity to angiotensin II in conscious, potassium-deficient rats.

Authors:  M S Paller; J G Douglas; S L Linas
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

9.  Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man.

Authors:  N K Hollenberg; W R Chenitz; D F Adams; G H Williams
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

10.  Effect of captopril and hydrochlorothiazide on the response to pressor agents in hypertensives.

Authors:  R J Fruncillo; H H Rotmensch; P H Vlasses; J R Koplin; B N Swanson; R K Ferguson
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.